Vir Biotechnology
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-04-07
- Employees
- 587
- Market Cap
- -
- Website
- http://www.vir.bio
- Introduction
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.
A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants
- Conditions
- Covid19
- Interventions
- Other: Placebo to BiologicBiological: sotrovimab
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Vir Biotechnology, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT04988152
- Locations
- 🇺🇸
Investigative Site, Glendale, California, United States
Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.
- Conditions
- Covid19
- Interventions
- Biological: Sotrovimab
- First Posted Date
- 2021-06-04
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Vir Biotechnology, Inc.
- Target Recruit Count
- 1065
- Registration Number
- NCT04913675
- Locations
- 🇺🇦
Investigative Site, Kyiv, Ukraine
🇺🇸Investigative Sites, Pembroke Pines, Florida, United States
Study of VIR-2218, VIR-3434, And/or PEG-IFNα in Subjects with Chronic Hepatitis B Virus Infection
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Vir Biotechnology, Inc.
- Target Recruit Count
- 244
- Registration Number
- NCT04856085
- Locations
- 🇬🇧
Investigative Site, Manchester, United Kingdom
Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19
- Conditions
- Covid19
- Interventions
- Biological: Sotrovimab (Gen1)Biological: Sotrovimab (Gen2)
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Vir Biotechnology, Inc.
- Target Recruit Count
- 354
- Registration Number
- NCT04779879
- Locations
- 🇪🇸
Investigative Site, Vigo, Spain
VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers
- Conditions
- HIV I Infection
- Interventions
- Biological: VIR-1111Drug: Placebo
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Vir Biotechnology, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT04725877
- Locations
- 🇺🇸
Investigative Site, Madison, Wisconsin, United States
VIR-7831 for the Early Treatment of COVID-19 in Outpatients
- Conditions
- Covid19
- Interventions
- Biological: VIR-7831 (sotrovimab)Drug: Placebo
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Vir Biotechnology, Inc.
- Target Recruit Count
- 1057
- Registration Number
- NCT04545060
- Locations
- 🇬🇧
Investigative Site, Belfast, United Kingdom
Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Vir Biotechnology, Inc.
- Target Recruit Count
- 113
- Registration Number
- NCT04423393
- Locations
- 🇬🇧
Investigative Site, Manchester, United Kingdom
Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection
- Conditions
- Chronic Hepatitis B
- Interventions
- Drug: pegylated interferon-alfa 2a
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Vir Biotechnology, Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT04412863
- Locations
- 🇹🇭
Investigative Site, Khon Kaen, Thailand
🇭🇰Investigative site, Hong Kong, Hong Kong
Study of VIR-2482 in Healthy Volunteers
- First Posted Date
- 2019-07-26
- Last Posted Date
- 2022-06-09
- Lead Sponsor
- Vir Biotechnology, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT04033406
- Locations
- 🇦🇺
Investigative Site, Brisbane, Queensland, Australia
Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2021-12-13
- Lead Sponsor
- Vir Biotechnology, Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT03672188
- Locations
- 🇹🇭
Investigative Site, Khon Kaen, Thailand